NCT03971409 2026-04-17
InCITe
University of California, San Francisco
Phase 2 Active not recruiting
Clinical Trials
13 trialsNCT00092222 2026-04-14
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT04739800 2026-04-13
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT04293393 2026-03-12
CARABELA
Spanish Breast Cancer Research Group
Phase 2 Active not recruiting
NCT05467670 2026-03-04
Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer
University of Pittsburgh
Phase 2 Active not recruiting
NCT06425302 2026-01-08
GOLSEEK-2
Celgene
Phase 2 Active not recruiting
NCT06630325 2026-01-07
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT04243616 2025-09-05
CemiHALT
Medical College of Wisconsin
Phase 2 Active not recruiting
NCT02734771 2025-08-12
BV mini CHP
University of Rochester
Phase 2 Active not recruiting
NCT04274426 2025-04-06
MIROVA
AGO Research GmbH
Phase 2 Active not recruiting
NCT02299999 2025-01-15
SAFIR02_Breast
UNICANCER
Phase 2 Active not recruiting
NCT02315196 2023-03-29
Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer
Rutgers, The State University of New Jersey
Phase 2 Active not recruiting